Scholars and studies funded by Susan G. Komen(R), the world鈥檚 leading breast cancer organization, showcased cutting-edge breast cancer research aimed at advancing the field at the ASCO Annual Meeting 2024. Organized by the American Society of Clinical Oncology, this premier conference annually convenes over 40,000 oncologists and stakeholders worldwide.
CAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4
A new 鈥渁rmored鈥� form of CAR T cell therapy may be able to help patients with non-Hodgkin lymphoma whose cancers do not respond to currently available CAR T cell therapies. The Phase I clinical trial was presented at the 2024 ASCO Annual Meeting.
How artificial intelligence tools could help predict colon cancer aggressiveness and how the gut microbiome might provide clues to the rapid rise in colon cancers among young people are among dozens of research studies being presented by The Ohio State University Comprehensive Cancer Center 鈥� Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC 鈥� James) at the 2024 American Society of Clinical Oncology annual meeting, which takes place May 31 through June 4 in Chicago, Illinois. Among other emerging health topics being discussed are the use of multicancer screening tests and how equity should be a critical point of consideration in the commercial development of these tools.
Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lymphoma, breast cancer, and glioblastoma. These findings are among more than 80 studies presented at ASCO that are led by Dana-Farber-affiliated researchers.
Researchers from The University of Texas MD Anderson Cancer Center presented positive clinical results from two studies today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Secondary analyses of a phase 3 clinical trial have revealed that breast cancer patients who reported high levels of pain and stress were more likely than their study peers to experience worse invasive disease-free survival (iDFS) and worse overall survival (OS).
Data from a large prospective cohort study reveal that a polygenic risk score has the potential to predict survival outcomes in patients with breast cancer.
20221027104337.jpg&width=400&height=400)
New research from Yale Cancer Center reveals first-of-its-kind data from a phase I study in patients with hormone receptor positive HER2-negative metastatic breast cancer. The results, which assess the safety and efficacy of a treatment known as PF-07248144, offer new hope for treating this aggressive type of breast cancer.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 麻豆传媒 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
